Ranpak Holdings Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ranpak Holdings Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $395.00M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $368.90M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $336.30M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $326.50M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $383.90M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $298.20M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $77.70M | Mar 17, 2020 |
| FY2019 | Sep 30, 2019 | $69.10M | Mar 17, 2020 |
| FY2019 | Jun 30, 2019 | $16.30M | Mar 17, 2020 |
| FY2019 | Jun 2, 2019 | $40.30M | Mar 17, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.70M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $315.50M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $284.80M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $276.40M | Mar 17, 2025 |
| FY2019 | Dec 31, 2019 | $140.70M | Mar 17, 2020 |
| FY2019 | Jun 2, 2019 | $91.80M | Mar 17, 2020 |
| FY2019 | Dec 31, 2018 | $229.20M | Mar 17, 2020 |
| FY2019 | Dec 31, 2017 | $209.70M | Mar 17, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.70M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $139.80M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $123.30M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $99.60M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $148.90M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $122.60M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $32.80M | Mar 17, 2020 |
| FY2019 | Sep 30, 2019 | $29.50M | Mar 17, 2020 |
| FY2019 | Jun 30, 2019 | $3.30M | Mar 17, 2020 |
| FY2019 | Jun 2, 2019 | $17.10M | Mar 17, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.30M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($21.50M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($27.10M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($41.40M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($2.80M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($23.40M) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | ($3.20M) | Mar 17, 2020 |
| FY2019 | Sep 30, 2019 | ($1.60M) | Mar 17, 2020 |
| FY2019 | Jun 30, 2019 | ($12.40M) | Mar 17, 2020 |
| FY2019 | Jun 2, 2019 | ($15.80M) | Mar 17, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.30M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($12.80M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($7.50M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($42.50M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $12.20M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $11.70M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $12.10M | Mar 17, 2020 |
| FY2019 | Sep 30, 2019 | $1.00M | Mar 17, 2020 |
| FY2019 | Jun 30, 2019 | ($5.10M) | Mar 17, 2020 |
| FY2019 | Jun 2, 2019 | ($8.20M) | Mar 17, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.10M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.40M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $3.70M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $3.60M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $1.70M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $2.30M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $900.0K | Feb 28, 2022 |
| FY2021 | Jun 2, 2019 | $1.20M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $2.40M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $2.20M | Mar 17, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.50M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $111.90M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $91.80M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $105.50M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $98.30M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $72.50M | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | $37.70M | Mar 4, 2021 |
| FY2021 | Jun 2, 2019 | $23.80M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $53.20M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $46.30M | Mar 17, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.10M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $41.40M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $52.60M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.10M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $54.30M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $63.80M | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | $9.60M | Mar 4, 2021 |
| FY2021 | Jun 2, 2019 | $16.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $42.00M | Mar 4, 2021 |
| FY2018 | Dec 31, 2017 | ($19.4K) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $55.30M | Mar 14, 2024 |
| FY2023 | Dec 31, 2022 | $44.80M | Mar 14, 2024 |
| FY2023 | Dec 31, 2021 | $54.50M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $32.30M | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | $19.20M | Mar 4, 2021 |
| FY2021 | Jun 2, 2019 | $10.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $24.80M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $27.00M | Mar 17, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.12B | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.13B | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $1.21B | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.13B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.10B | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $792.70M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $870.8K | Mar 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $590.00M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $556.10M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $550.70M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $520.70M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $577.20M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $610.60M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $572.60M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $596.30M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $816.8K | Mar 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $534.90M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $548.10M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $572.00M | Mar 5, 2026 |
| FY2025 | Dec 31, 2022 | $612.80M | Mar 5, 2026 |
| FY2024 | Dec 31, 2021 | $636.20M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | $522.90M | Mar 14, 2024 |
| FY2022 | Dec 31, 2019 | $531.80M | Mar 31, 2023 |
| FY2021 | Jun 3, 2019 | $5.00M | Feb 28, 2022 |
| FY2021 | Jun 2, 2019 | $173.40M | Feb 28, 2022 |
| FY2021 | Dec 31, 2018 | $196.40M | Feb 28, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $457.20M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $443.70M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $450.10M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $446.70M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $453.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $458.40M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $448.80M | Feb 28, 2022 |
| FY2020 | Jun 3, 2019 | $0 | Mar 4, 2021 |
| FY2020 | Jun 2, 2019 | $353.20M | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $355.70M | Mar 4, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($183.60M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($145.30M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($123.80M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($96.70M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($55.30M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($52.50M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($29.10M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($69.90M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($8.5K) | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.00M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $76.10M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $62.00M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $62.80M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $103.90M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $48.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $19.70M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $17.50M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.9K | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $401.90M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $406.40M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $400.30M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $393.00M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $401.40M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $433.20M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $420.40M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $506.50M | Mar 17, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 4, 2021 |
| FY2022 | Jun 2, 2019 | (19,195) | Mar 31, 2023 |
| FY2020 | Dec 31, 2018 | (8,697) | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | 27,801 | Mar 17, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 4, 2021 |
| FY2021 | Jun 2, 2019 | (19,195) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | (8,697) | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | 27,801 | Mar 17, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 84.39M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 83.27M | Mar 5, 2026 |
| FY2021 | Dec 31, 2021 | 81.40M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | 75.52M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 70.81M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 995 | Mar 17, 2020 |